<table border="1"><tr><th>Trade names</th><td>Isentress</td></tr><tr><th>Other names</th><td>RAL</td></tr><tr><th>AHFS/Drugs.com</th><td>Monograph</td></tr><tr><th>MedlinePlus</th><td>a608004</td></tr><tr><th>License data</th><td>EU |  EMA | by INN | US |  DailyMed | Raltegravir | US | FDA: Raltegravir</td></tr><tr><th>Pregnancy | category</th><td>AU |  B3</td></tr><tr><th>Routes of | administration</th><td>By mouth</td></tr><tr><th>ATC code</th><td>J05AJ01 ( | WHO | )</td></tr><tr><th>Legal status</th><td>UK |  POM (Prescription only) | US |  ℞-only | EU |  Rx-only</td></tr><tr><th>Bioavailability</th><td>60% (FDA)</td></tr><tr><th>Protein binding</th><td>83%</td></tr><tr><th>Metabolism</th><td>Liver (UGT1A1)</td></tr><tr><th>Elimination | half-life</th><td>9 hours</td></tr><tr><th>Excretion</th><td>feces and urine</td></tr><tr><th>Identifiers</th><td>IUPAC name | N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-2-(2-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}-2-propanyl)-6-oxo-1,6-dihydro-4-pyrimidinecarboxamide</td></tr><tr><th>CAS Number</th><td>518048-05-0</td></tr><tr><th>PubChem | CID</th><td>54671008</td></tr><tr><th>DrugBank</th><td>DB06817</td></tr><tr><th>ChemSpider</th><td>16445111</td></tr><tr><th>UNII</th><td>22VKV8053U</td></tr><tr><th>KEGG</th><td>D06676 | as salt | D07133</td></tr><tr><th>ChEBI</th><td>CHEBI:82960</td></tr><tr><th>ChEMBL</th><td>ChEMBL254316</td></tr><tr><th>NIAID ChemDB</th><td>471309</td></tr><tr><th>PDB ligand</th><td>RLT ( | PDBe | , | RCSB PDB | )</td></tr><tr><th>CompTox Dashboard | ( | EPA | )</th><td>DTXSID2048660</td></tr><tr><th>ECHA InfoCard</th><td>100.124.631</td></tr><tr><th>Formula</th><td>C | 20 | H | 21 | F | N | 6 | O | 5</td></tr><tr><th>Molar mass</th><td>444.423 |  g·mol | −1</td></tr><tr><th>3D model (JSmol)</th><td>Interactive image</td></tr></table>